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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idAlthough most individuals with a Giardia infection are
asymptomatic, this pathogen is increasingly recognized as a cause
of pathologies beyond the classical manifestations.1 Morbidities
associated with Giardia, including extra-intestinal manifestations
and long-term consequences, have been identiﬁed increasingly
over the past decades.2–4 The importance of this pathogen in terms
of patient well-being and its effect on quality of life, due to being a
continuing cause of patient discomfort and pain, has been
highlighted .5
Unfortunately, giardiasis is not a health priority. This may be
due to a lack of political will, funding, or interest from the scientiﬁc
community (more focused on other scientiﬁc priorities), or to
public indifference, but is most likely a combination of all of these
factors. Nowadays, regardless of the stage of economic develop-
ment of the affected countries, neglect of this protozoan disease is
not the best option. Numerically speaking, giardiasis has never
been a minor disease, even for many industrialized countries; thus,
the sheer volume affected and the problems it causes warrant
reﬂection regarding control strategies.
The sequelae of Giardia infections are of considerable scientiﬁc
interest as well as of public health signiﬁcance. Recently a large
controlled prospective study of a cohort of individuals who had
conﬁrmed Giardia infections during a waterborne outbreak in
Norway was published.6 In that study, a signiﬁcantly increased risk
of both irritable bowel syndrome (IBS) and chronic fatigue (CF),
even 6 years after the infection, was documented; fortunately,
these decreased over time, indicating that Giardia may elicit very
long-term, but slowly self-limiting complications. These data add
to an all too slowly growing body of Giardia research, which, taken
in aggregate, suggest that the time has come to encourage
increased investigations.
In this issue of the International Journal of Infectious Diseases, we
present an analysis of the incidence of IBS without diarrhoea in the
departments of Colombia during 2013. This was signiﬁcantly
associated with the incidence of giardiasis (r2 = 0.7457;
p < 0.0001). Departments with higher giardiasis incidence had
higher reported IBS (Figure 1), coinciding ecologically with the
ﬁndings of the Norway study.
Current discussion on the natural course of IBS and CF after
Giardia infection has been enriched, whether manifested by
classical signs and symptoms or a less straightforward clinical
presentation . Important contributions have been made regarding
the spectrum of illness attributable to giardiasis. It is illustratedDOI of original article: http://dx.doi.org/10.1016/j.ijid.2016.06.005
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).that the potential development of sequelae may include both IBS
and CF, in spite of the eradication of the organism. Additionally,
this has opened new avenues of research. Further investigations on
the pathogenic mechanisms behind the development of these two
conditions are needed, which could lead to potential interventions
to prevent them. This study also provides a clue to physicians
whose patients do not respond with symptom resolution after
successful therapy. They need to be aware of the potential sequelae
of Giardia infection, to alert their patients of the possible
importance of reporting a previous Giardia exposure when
presenting for treatment if CF or IBS symptoms develop.
In summary, there remains much to be known about Giardia
and the spectrum of disease it causes, its epidemiology, and
treatment. Collaborative studies that focus on determining
precisely those who are most prone to develop CF or IBS after
this infection are needed. Up to now, only old age and female sex
have been identiﬁed as high risk factors for post-infectious
fatigue.7,8 It is also important to determine whether the treatment
– and the timing of initiation – might inﬂuence these outcomes.Figure 1. Non-linear regression model between giardiasis incidence rates (cases/
100 000 population) and irritable bowel syndrome (IBS) incidence rates (cases/
100 000 population) by department, Colombia, 2013.
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post-elimination could be more frequent in those who have
experienced chronic or treatment-refractory giardiasis.9 Is there
any therapeutic window for possible early intervention to avoid
CF and/or IBS? Stratiﬁcation among patients susceptible to these
complications according medical, immunological, and/or epide-
miological proﬁles is needed to identify determinants of these
clinical expressions. The Giardia isolates from patients developing
long-term sequelae also deserve further study, as they may be
genetically different.
The study setting is also important when interpreting the
results. It is also necessary to characterize the parasite genotype
pattern in the region and to determine whether newly introduced
genotypes could produce a synergistic interaction which could
result in greater pathogenicity. Last, but not least, it is also
important to evaluate the impact of Giardia infection and its post-
infectious sequelae in low-income countries, where there is the
greatest burden of disease and highest risk of transmission.
Fortunately, research on giardiasis is growing,10 since there is
no doubt that for Giardia infection, there are still many questions to
be answered. Up to now, the more you look, the more you ﬁnd.
However, a question arises: ‘‘How much is there?’’
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